Logo
x

Search

Subscribe Now

Talazoparib

Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer

Myriad and Pfizer Signs a Service Agreement for Testing of BRCA-Mutated Triple Negative Breast Cancer

  • October 12, 2018
Pfizer's Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated- HER2-Negative LA or MBC

Pfizer's Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated- HER2-Negative LA or MBC

  • October 11, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.